Clinical Trials Logo

Filter by:
NCT ID: NCT05824247 Recruiting - Ovarian Cancer Clinical Trials

A Prospective Cohort Study of 68ga-FAPI-pet-ct Versus FDG-pet-ct for Ovarian Cancer

Start date: April 1, 2022
Phase:
Study type: Observational

A study to discuss the advantage of Fapi PET- CT in the initial diagnosis staging and lesion determination of ovarian cancer,whether it can be a evaluation strategy as an R0 evaluation tool or a prediction tool of chemotherapy response and evaluation of prognosis.

NCT ID: NCT05824169 Recruiting - Clinical trials for Spinal Muscular Atrophy

Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 1 Patients

Start date: February 25, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The study will evaluate safety and efficacy of intrathecal delivery of GC101 gene therapy drug as a treatment of spinal muscular atrophy Type 1 (SMA 1) patients.

NCT ID: NCT05823987 Recruiting - Clinical trials for Advanced Biliary Tract Cancer

Oncolytic Virotherapy Combined With Tislelizumab Plus Lenvatinib in Patients With Advanced Biliary Tract Cancer (OPTIONS-05)

OPTIONS-05
Start date: May 16, 2023
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of oncolytic virotherapy combined with Tislelizumab plus lenvatinib in patients with advanced biliary tract cancer (BTC).

NCT ID: NCT05823792 Recruiting - Clinical trials for Ileocolic Intussusception

Performance of Artificial Intelligence Tools and Ultrasonographers With Different Skills

PAITUWDS
Start date: April 9, 2023
Phase:
Study type: Observational

Artificial intelligence versus different skilled sonographers.

NCT ID: NCT05823714 Recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax+Azacytidine+Modified BUCY Conditioning Regimen for Acute Myeloid Leukemia and Myelodysplastic Syndromes Undergoing Allo-HSCT

Start date: January 20, 2022
Phase: Phase 2
Study type: Interventional

The purpose of this prospective, open-label, single-center study is to evaluate the efficacy and safety of VEN-AZA (venetoclax and azacytidine) followed by modified BUCY (busulfan and cyclophosphamide) as conditioning regimen for high-risk myelodysplastic syndrome (MDS) and high-risk or relapsed/refractory acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).

NCT ID: NCT05823701 Recruiting - Clinical trials for Diffuse Large B-Cell Lymphoma

Chidamide, Azacitidine Combined With GM Regimen for Relapsed and Refractory DLBCL Patients

Start date: September 30, 2022
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of CAGM regimen in R/R DLBCL patients and to provide a safe and more effective approach for R/R DLBCL patients.

NCT ID: NCT05823675 Recruiting - Clinical trials for Acute Graft Versus Host Disease

Safety and Clinical Activity of Itolizumab in aGVHD

Start date: May 19, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerability, PK, PD, and clinical activity of Itolizumab in subjects with Newly diagnosed Acute Graft Versus Host Disease(aGVHD).

NCT ID: NCT05823636 Recruiting - Dyspepsia Clinical Trials

The Clinical Course and Factors for the Progression of Uninvestigated Dyspepsia to Functional Dyspepsia

Start date: January 1, 2023
Phase:
Study type: Observational

Dyspepsia is one of the most common gastrointestinal diseases. This disease was defined as predominant epigastric pain lasting for at least 1 month, which can be accompanied with other symptoms, such as epigastric fullness, and early satiety. Despite dyspepsia symptoms lasting for ≥1 month represented clinical problem, a longer duration of 6 months or more after first-onset symptom was required for the diagnosis of functional dyspepsia based on ROME IV criteria. It was unclear about the natural procession of first-onset dyspepsia to functional dyspepsia assessed by Rome IV or Asia criteria and possible factors associated with this progression.

NCT ID: NCT05823623 Recruiting - Breast Cancer Clinical Trials

Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer

Start date: February 13, 2022
Phase: Phase 2
Study type: Interventional

In this phase 2 single-arm clinical trial, 30 patients with HER2-positive metastatic breast cancer after progression on trastuzumab are enrolled and receive treatment of Inetetamab plus Pyrotinib plus Oral Vinorelbine. The study aimed to access the efficacy and safety of Inetetamab combined with Pyrotinib and Oral Vinorelbine in HER2-positive metastatic breast cancer patients after progression on trastuzumab.

NCT ID: NCT05823493 Completed - Clinical trials for Adolescent Idiopathic Scoliosis

Effect of Schroth Exercises Combined With Laser Acupuncture Therapy in Adolescent Idiopathic Scoliosis

Start date: March 1, 2021
Phase: N/A
Study type: Interventional

The goal of this clinical trial] is to explore the clinical effect of laser acupuncture combined with Schroth training on adolescent idiopathic scoliosis (AIS) . The main question[s] it aims to answer are: - The effects of Schroth exercises on Cobb angles, angle of trunk rotation, spinal mobility, gait parameters and clinical efficacy in patients with AIS. - Laser acupuncture combined with Schroth method on Cobb angles, angle of trunk rotation, spinal mobility, gait parameters and clinical efficacy in patients with AIS. Participants will received Schroth exercise therapy and laser acupuncture therapy (MLS laser). If there is a comparison group: Researchers will compare received Schroth exercise therapy to see the effects of Schroth exercises and laser acupuncture combined with Schroth method on Cobb angles, angle of trunk rotation, spinal mobility, gait parameters and clinical efficacy in patients with AIS